Phase 2b Trial of Mizagliflozin for Post-Bariatric Hypoglycemia Initiated by Vogenx, Inc.
Vogenx, Inc. has initiated Phase 2b trial (VGX-001-013) to evaluate mizagliflozin for preventing hypoglycemia in post-bariatric patients.
Asset / Drug
Drug and asset intelligence for Mizagliflozin with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.